Primary Antibodies
Primary Antibodies
ACROBiosystems ACROBiosystems Anti-Adalimumab Antibodies
Antibody;1MG;IgG1/kappa;Recognizes Adalimumab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Adalimumab F(ab')2.; ;Anti-Adalimumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized adalimumab at 1 µg/mL, add increasing concentrations of Anti-Adalimumab Antibodies (Cat. No. ADB-Y19, 10% human serum) and then add biotinylated adalimumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 0.6 ng/mL. ;Demonstration of the specificity of Anti-Adalimumab Antibodies (Cat. No. ADB-Y19) to the adalimumab.;Anti-Adalimumab Antibodies (mouse IgG1, Cat. No. ADB-Y19) captured on CM5 chip via anti-mouse antibodies surface, can bind human adalimumab with an affinity constant of 1.36 pM.
ACROBiosystems ACROBiosystems Anti-Adalimumab Antibodies
Antibody;100UG;IgG1/kappa;Recognizes Adalimumab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Adalimumab F(ab')2.; ;Anti-Adalimumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized adalimumab at 1 µg/mL, add increasing concentrations of Anti-Adalimumab Antibodies (Cat. No. ADB-Y19, 10% human serum) and then add biotinylated adalimumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 0.6 ng/mL. ;Demonstration of the specificity of Anti-Adalimumab Antibodies (Cat. No. ADB-Y19) to the adalimumab.;Anti-Adalimumab Antibodies (mouse IgG1, Cat. No. ADB-Y19) captured on CM5 chip via anti-mouse antibodies surface, can bind human adalimumab with an affinity constant of 1.36 pM.
ACROBiosystems ACROBiosystems Anti-Cetuximab Antibodies
Antibody;1MG;IgG1/kappa;Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab')2.; ;Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28, 10% human serum) and then add biotinylated cetuximab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 2.4 ng/mL. ;Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28) to the cetuximab.;Anti-Cetuximab Antibodies (mouse IgG1, Cat. No. CEB-Y28) captured on CM5 chip via anti-mouse antibodies surface, can bind Human cetuximab with an affinity constant of 1.51 pM.
ACROBiosystems ACROBiosystems Anti-Cetuximab Antibodies
Antibody;100UG;IgG1/kappa;Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab')2.; ;Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28, 10% human serum) and then add biotinylated cetuximab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 2.4 ng/mL. ;Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28) to the cetuximab.;Anti-Cetuximab Antibodies (mouse IgG1, Cat. No. CEB-Y28) captured on CM5 chip via anti-mouse antibodies surface, can bind Human cetuximab with an affinity constant of 1.51 pM.
ACROBiosystems ACROBiosystems Anti-Rituximab Antibodies (MALS verified)
Antibody;100UG;IgG1 / kappa;Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.;Anti-Rituximab Antibodies (RIB-Y35c) are expressed from human 293 cells (HEK293).;This protein . ;Immobilized Rituximab at 1 μg/mL (100 μL/well) can bind Anti-Rituximab Antibodies (Cat. No. RIB-Y35c) with a linear range of 0.2-6 ng/mL (QC tested).
ACROBiosystems ACROBiosystems Human CD47-coupled Magnetic Beads
Beads;2MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
ACROBiosystems ACROBiosystems Human CD47-coupled Magnetic Beads
Beads;10MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
ACROBiosystems ACROBiosystems Anti-Cetuximab Antibodies (Non-Neutralizing)
Antibody;1MG;IgG1/kappa;Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab')2.; ;Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibodies (Cat. No. CEB-Y31, 10% human serum) and then add biotinylated cetuximab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 39 ng/mL. ;Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y31) to the cetuximab.;Anti-Cetuximab Antibodies (mouse IgG1, Cat. No. CEB-Y31) captured on CM5 chip via anti-mouse antibodies surface, can bind human cetuximab with an affinity constant of 0.421 nM.
ACROBiosystems ACROBiosystems Human ANGPT2-coupled Magnetic Beads
Beads;2MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications. ;Immobilized 47μg ANGPT2 protein/1mg beads can bind Human TIE2 Protein, Fc Tag (Cat.No. TI2-H5255) with an EC50 of 3.228 μg/mL (QC tested).
ACROBiosystems ACROBiosystems Human Mesothelin-coupled Magnetic Beads
Beads;10MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
ACROBiosystems ACROBiosystems Human ANGPT2-coupled Magnetic Beads
Beads;10MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications. ;Immobilized 47μg ANGPT2 protein/1mg beads can bind Human TIE2 Protein, Fc Tag (Cat.No. TI2-H5255) with an EC50 of 3.228 μg/mL (QC tested).
ACROBiosystems ACROBiosystems Human CD73-coupled Magnetic Beads
Beads;10MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications. ;Immobilized 62 μg CD73 protein to 1 mg Beads can bind the Anti-CD73 Antibody with an EC50 of 0.5659 μg/mL (QC tested).
ACROBiosystems ACROBiosystems Anti-Rituximab Antibodies (MALS verified)
Antibody;1MG;IgG1 / kappa;Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.;Anti-Rituximab Antibodies (RIB-Y35c) are expressed from human 293 cells (HEK293).;This protein . ;Immobilized Rituximab at 1 μg/mL (100 μL/well) can bind Anti-Rituximab Antibodies (Cat. No. RIB-Y35c) with a linear range of 0.2-6 ng/mL (QC tested).
ACROBiosystems ACROBiosystems Human EGFRvIII-coupled Magnetic Beads
Beads;2MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications. ;Immobilized 44 μg EGFRvIII protein/1 mg beads can bind Anti-EGFR Antibody (Cetuximab) with an EC50 of 0.7172 μg/mL (QC tested).;Immobilized 44 μg EGFRvIII protein/1mg beads can bind Anti-EGFRvIII Antibody with an EC50 of 0.8856 μg/mL (QC tested).
ACROBiosystems ACROBiosystems Human EGFRvIII-coupled Magnetic Beads
Beads;10MG;The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications. ;Immobilized 44 μg EGFRvIII protein/1 mg beads can bind Anti-EGFR Antibody (Cetuximab) with an EC50 of 0.7172 μg/mL (QC tested).;Immobilized 44 μg EGFRvIII protein/1mg beads can bind Anti-EGFRvIII Antibody with an EC50 of 0.8856 μg/mL (QC tested).